We provide you with 20 years of free, institutional-grade data for INAB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of INAB. Explore the full financial landscape of INAB stock.
| Reported Date | CIK | Ticker | Type |
|---|
IN8bio, Inc.(NASDAQ:INAB) 
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I cli...
Share this website to your friends
The information provided in this report about INAB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.